Non-respiratory revenue rose 12.3% to 62.4 billion won in Q3

Molecular diagnostics company Seegene increased its earnings even during the off-season for respiratory infections. Sales of diagnostic products for non-respiratory infections, including human papillomavirus (HPV), a cause of cervical cancer, and gastrointestinal infections, drove growth and diversified a revenue structure that had been concentrated in respiratory infection seasons.


According to industry sources on November 17, Seegene's preliminary results for the third quarter of this year showed that revenue from non-respiratory products rose 12.3% year over year to 62.4 billion won. This accounted for more than half of total revenue of 123.1 billion won. By product, sales of HPV tests increased 19.7%, gastrointestinal infection (GI) tests rose 12.6%, and sexually transmitted infection (STI) tests grew 6.7%. Total revenue and operating profit, which came to 11.6 billion won, increased 8.4% and 21.2%, respectively.


Seegene corporate logo image. Seegene

Seegene corporate logo image. Seegene

View original image

The third quarter is the time of year when demand for tests for respiratory infections such as influenza and COVID-19 is at its lowest. Seegene has a large share of revenue from respiratory testing products, and its results have therefore fluctuated with the prevalence of respiratory infections. The company's third-quarter growth is notable because it came from increased sales of non-respiratory products outside the respiratory infection season.


In fact, demand for respiratory tests declined across the global diagnostics industry in the third quarter of this year, as respiratory pathogens spread less widely than they did last year. French diagnostics company bioMerieux reported an 8% year-over-year decline in respiratory panel revenue for the third quarter.


By contrast, sales of non-respiratory tests increased across the industry. bioMerieux's non-respiratory panel revenue rose 25% over the same period. The increase was largely driven by a rise in gastrointestinal tests amid an outbreak of cyclosporiasis, a parasitic infection, in the United States. The company estimated that growth would have been about 15% even excluding this one-off factor. Revenue from the "syndromic testing" system of German molecular diagnostics company QIAGEN also rose 11%. Gastrointestinal infection and meningitis and encephalitis test panels drove the growth.


Syndromic tests, a core product of these companies, detect multiple pathogens that can cause the same symptoms in a single test. These include respiratory panels for patients with coughs and fevers, gastrointestinal panels for patients with diarrhea, and meningitis and sexually transmitted infection panels.


Having confirmed the growth of its non-respiratory products in its third-quarter results, Seegene is also pursuing a "comprehensive testing" strategy centered on syndromic PCR tests and automated equipment. This approach uses respiratory and non-respiratory test products to test for multiple pathogens at once, identifying the causative pathogen and whether there is a co-infection.


The industry expects syndromic testing and diversification of diagnostic products to become increasingly important as demand for respiratory tests declines and non-respiratory tests drive growth. Seegene is also focusing on expanding its non-respiratory product portfolio to shift its revenue structure away from its concentration in respiratory testing.



Kim Jeongyong, Seegene's head of finance, said while announcing the company's third-quarter results on November 6, "Our key non-respiratory product lines, including HPV, GI and STI, are growing evenly, diversifying our revenue base. We will strengthen our mid- to long-term growth drivers by expanding the markets for existing products while advancing next-generation diagnostic solutions."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing